The drugmaker reports positive Phase 1b study results for its experimental gene therapy, Verve-102.

In its latest earnings report, Eli Lilly and Company (NYSE: LLY) once again showed why it has become by far one of the world’s most valuable healthcare stocks. Year-to-date, Eli Lilly’s market ...

Lilly leads the obesity medicine race. Novo built the metabolic drug market. Amgen adds a biotech challenger angle. Obesity ...

The highest dose of a single injection reduced cholesterol levels by 62% in patients, according to Eli Lilly's recently ...

Eli Lilly (NYSE: LLY) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit revenue growth, taken leadership in the market, and seen its stock price ...

Eli Lilly (NYSE:LLY) has agreed to acquire Engage Biologics in a deal worth up to $202 million. Engage Biologics is developing Tethosome, a non-viral DNA delivery platform for genetic medicines. This ...

Eli Lilly (NYSE:LLY) has built one of the most remarkable growth stories in modern pharmaceutical history through its GLP-1 franchises. Mounjaro and Zepbound conquered the weight-loss market, giving ...

INDIANAPOLIS (REUTERS) — Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a ...

Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years. Eli Lilly dominates the GLP-1 market in the U.S. Eli Lilly (NYSE: LLY) has already ...